From Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation

After more than two decades leading organisations at some of the world’s most respected medical device companies, including Hologic, SenoRx Breast Care, and BTL Industries, Joseph B. LaBruzzo is embarking on a new chapter as President & CEO of U.S. Operations and Board Member at Ark Surgical.

We sat down with Joseph to discuss what drew him to Ark Surgical, why he believes women’s surgical innovation is entering a transformative era, and what it takes to bring meaningful technologies from concept to standard of care.

You have held leadership positions at some of the biggest names in MedTech. What attracted you to Ark Surgical?

Throughout my career, I’ve been fortunate to work with organisations that developed technologies capable of changing the standard of care.

What attracted me to Ark Surgical is the opportunity to help address a meaningful unmet need in gynecologic surgery with an innovation that has the potential to improve patient outcomes while preserving the benefits of minimally invasive surgery.

Opportunities like that don’t come along very often.

FemTech World recently highlighted that many women remain unaware of gynecologic cancers and that unexpected diagnoses continue to have a profound impact on patients and families.

How has your own experience shaped the way you think about innovation in women’s health?

Earlier in my career, I witnessed many women receive life-changing cancer diagnoses.

Those experiences stayed with me and reinforced my belief that if there’s an opportunity to reduce risk through better innovation, it’s one worth pursuing.

That’s one of the reasons I was drawn to Ark Surgical.

The vast majority of minimally invasive gynecologic procedures are performed for conditions believed to be benign. Unfortunately, in rare cases, pathology later reveals an unexpected malignancy.

LapBox was designed with a proprietary dual-wall tissue containment system to help facilitate contained specimen retrieval and minimise the risk of tissue spillage during laparoscopic procedures.

I believe innovations like this can help surgeons manage the unexpected while preserving the many benefits of minimally invasive surgery for women.

Women’s health has gained significant momentum in recent years, yet surgical innovation often receives less attention than diagnostics or therapeutics. Why do you think that is?

Women’s health has historically been underfunded and underserved across many areas of medicine, and surgery is no exception.

While we’ve seen tremendous advances in diagnostics and pharmaceuticals, there are still important opportunities to improve the surgical experience for both physicians and patients.

Innovation that enhances safety, efficiency, and outcomes has the potential to make a lasting impact.

What excites you most about LapBox?

LapBox addresses a very real challenge that gynecologic surgeons face during minimally invasive procedures.

It was thoughtfully designed to integrate seamlessly into the surgical workflow while providing an added layer of confidence when tissue retrieval is required.

I believe technologies that solve real clinical challenges in a practical way have the greatest potential to become part of the standard of care.

What do you see as the biggest unmet needs in minimally invasive gynecologic surgery today?

The future of surgery isn’t simply about making procedures less invasive. It’s about making them smarter and safer.

Surgeons need technologies that integrate seamlessly into their workflow while helping them navigate increasingly complex clinical situations.

Every advancement that helps reduce risk while preserving the benefits of minimally invasive surgery has the potential to improve outcomes for both physicians and patients.

That’s where I believe the greatest opportunities for innovation exist.

As you take on this new role, what are your priorities over the next 12 months?

Our focus over the next 12 months is to build a strong foundation for growth. That means expanding physician partnerships, driving early clinical adoption, growing our team, and ensuring that more surgeons have access to technologies like LapBox.

At the same time, we’re focused on building strategic relationships with investors, healthcare systems, and industry partners that support our long-term vision.

What advice would you give entrepreneurs building the next generation of women’s health companies?

Start with a real clinical problem and never lose sight of the patient.

Great technology alone isn’t enough. You also need strong clinical evidence, physician advocates, and a clear market strategy. The companies that succeed are the ones that bring all of those pieces together while remaining focused on improving patient care.

About Joseph B. LaBruzzo

As President & CEO of U.S. Operations and Board Member, Joseph LaBruzzo is leading Ark Surgical’s U.S. growth strategy, physician partnerships, strategic investment initiatives, and organisational expansion, supporting the company’s mission to advance safer minimally invasive gynecologic surgery through innovative technologies.